Vascular endothelial growth factor (VEGF) antagonists for central retinal vein occlusion: an update on clinical progress

References

• SCORE2 Investigator Group, Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072–2087.
   PubMed Web of Science ®Google Scholar
• Rogers S, McIntosh RL, Cheung N, et al. International Eye disease consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmol. 2010;117(2):313–319, e1. doi: 10.1016/j.ophtha.2009.07.017
   PubMed Web of Science ®Google Scholar
• Ponto KA, Elbaz H, Peto T, et al. Prevalence and risk factors of retinal vein occlusion: the gutenberg Health study. J Thromb Haemost. 2015;13(7):1254–1263. doi: 10.1111/jth.12982
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: the beaver dam Eye study. Trans Am Ophthalmol Soc. 2000;98:133–141.
   PubMedGoogle Scholar
• Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the blue mountains Eye study. Arch Ophthalmol. 1996;114(10):1243–1247. doi: 10.1001/archopht.1996.01100140443012
   PubMed Web of Science ®Google Scholar
• Laouri M, Chen E, Looman M, et al. The burden of disease of retinal vein occlusion: review of the literature. Eye (Lond). 2011;25(8):981–988. doi: 10.1038/eye.2011.92
   PubMed Web of Science ®Google Scholar
• Liu W, Xu L, Jonas JB. Vein occlusion in Chinese subjects. Ophthalmol. 2007;114(9):1795–1796. doi: 10.1016/j.ophtha.2007.03.010
   PubMed Web of Science ®Google Scholar
• Yasuda M, Kiyohara Y, Arakawa S, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the hisayama study. Invest Ophthalmol Vis Sci. 2010;51(6):3205‑3209. doi: 10.1167/iovs.09-4453
   PubMed Web of Science ®Google Scholar
• Lim LL, Cheung N, Wang JJ, et al. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008;92(10):1316–1319. doi: 10.1136/bjo.2008.140640
   PubMed Web of Science ®Google Scholar
• Cheung N, Klein R, Wang JJ, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 2008;49(10):4297‑4302. doi: 10.1167/iovs.08-1826
   Web of Science ®Google Scholar
• Song P, Xu Y, Zha M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Global Health. 2019;9(1):010427. doi: 10.7189/jogh.09.010427
   PubMed Web of Science ®Google Scholar
• Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115(4):486–491. doi: 10.1001/archopht.1997.01100150488006
   PubMedGoogle Scholar
• Clarkson JG, Chuang E, Gass D. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M report. Ophthalmol. 1995;102(10):1425–1433. doi: 10.1016/S0161-6420(95)30849-4
   PubMed Web of Science ®Google Scholar
• Opremcak EM, Bruce RA, Lomeo MD, et al. Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases. Retina. 2001;21(5):408–415. doi: 10.1097/00006982-200110000-00002
   PubMed Web of Science ®Google Scholar
• McAllister IL, Constable IJ. Laser-induced chorioretinal venous anastomosis for treatment of nonischemic central retinal vein occlusion. Arch Ophthalmol. 1995;113(4):456–462. doi: 10.1001/archopht.1995.01100040072030
   PubMedGoogle Scholar
• Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmol. 2001;108(12):2249–2257. doi: 10.1016/S0161-6420(01)00875-2
   PubMed Web of Science ®Google Scholar
• SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101–1114.
   PubMedGoogle Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. For the OZURDEX GENEVA* study group. randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmol. 2010;117:1134–1146.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851–858. doi: 10.1016/0006-291X(89)92678-8
   PubMed Web of Science ®Google Scholar
• Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84(5):1470–1478. doi: 10.1172/JCI114322
   PubMed Web of Science ®Google Scholar
• Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77–88. doi: 10.1016/j.mayocp.2011.10.001
   PubMed Web of Science ®Google Scholar
• Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101–1114. doi: 10.1001/archophthalmol.2009.234
   PubMedGoogle Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. For the OZURDEX GENEVA study group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmol. 2010;117(6):1134–1146. doi: 10.1016/j.ophtha.2010.03.032
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;334(14):1432–1444. doi: 10.1056/NEJMoa062655
   Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi: 10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmol. 2012;119(4):789–801. doi: 10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Brown DM, Campochiaro PA, Singh RP, et al. For the CRUISE investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmol. 2010;117(6):1124–1133,e1. doi: 10.1016/j.ophtha.2010.02.022
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmol. 2012;119(12):2537–2548. doi: 10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Korobelnik J-K, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmol. 2014;121(11):2247–2254. doi: 10.1016/j.ophtha.2014.05.006
   PubMed Web of Science ®Google Scholar
• Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmol. 2012;119(5):1024–1032. doi: 10.1016/j.ophtha.2012.01.042
   PubMed Web of Science ®Google Scholar
• Holz FG, Roider J, Ogura Y, et al. VEGF trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284. doi: 10.1136/bjophthalmol-2012-301504
   PubMed Web of Science ®Google Scholar
• for the COLUMBUS-AMD Study Group, Holz FG, Oleksy P, Ricci F, et al. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmol. 2022;129(1):54–63.
   PubMed Web of Science ®Google Scholar
• Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139(1):68–76. doi: 10.1001/jamaophthalmol.2020.5053
   PubMed Web of Science ®Google Scholar
• Ip M, Hendrick A. Retinal vein occlusion Review. Asia-Pac J Ophthalmol. 2017;7(1):40–45. doi: 10.22608/APO.2017163442
   PubMed Web of Science ®Google Scholar
• The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116(3):286‒296. doi: 10.1016/S0002-9394(14)71345-5
   Web of Science ®Google Scholar
• Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol. 1993;37(6):393‒417. doi: 10.1016/0039-6257(93)90138-W
   PubMed Web of Science ®Google Scholar
• Lahey JM, Tunc M, Kearney J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmol. 2002;109(1):126‒131. doi: 10.1016/S0161-6420(01)00842-9
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman MB, Beri M, et al. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmol. 2004;111(1):133‒141. doi: 10.1016/j.ophtha.2003.03.002
   PubMed Web of Science ®Google Scholar
• Braithwaite T, Nanji AA, Lindsley K, et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;5(5). CD007325. doi: 10.1002/14651858.CD007325.pub3
   Google Scholar
• Holz FG, Roider J, Ogura Y, et al. VEGF trap‑eye for macular oedema secondary to central retinal vein occlusion: 6‑month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284. doi: 10.1136/bjophthalmol-2012-301504
   PubMed Web of Science ®Google Scholar
• Brown DM, Wykoff CC, Wong TP, et al. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the Rubeosis Anti-VEGF (RAVE) trial. Retina. 2014;34(9):1728–1735. doi: 10.1097/IAE.0000000000000191
   PubMed Web of Science ®Google Scholar
• Wecker T, Ehlken C, Bühler A, et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2017;101(3):353–359. doi: 10.1136/bjophthalmol-2016-308668
   PubMed Web of Science ®Google Scholar
• Callizo J, Ziemssen F, Bertelmann T, et al. real-world data: ranibizumab treatment for retinal vein occlusion in the OCEAN study. Clin Ophthalmol Volume 13: 13;2167–2179. 10.2147/OPTH.S209253.
   Web of Science ®Google Scholar
• Bhisitkul RB, Blotner S, Steffen V, et al. Clinical trial versus real-world outcomes with anti-VEGF therapy for central retinal vein occlusion. Invest Ophthalmol Visual Sci. 2020;61:1304.
   Web of Science ®Google Scholar
• Ciulla T, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. Br J Ophthalmol. 2021;105(12):1696–1704. doi: 10.1136/bjophthalmol-2020-317337
   PubMed Web of Science ®Google Scholar
• Chatziralli I, Theodossiadis G, Moschos MM, et al. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1093–1100. doi: 10.1007/s00417-017-3613-1
   PubMed Web of Science ®Google Scholar
• for the LEAVO Study Group, Hykin P, Prevost AT, et al. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion a randomized clinical trial. JAMA Ophthalmol. 2019;137(11):1256–1264.
   PubMed Web of Science ®Google Scholar
• Office of Inspector General, Department of Health and Human Services. Medicare payments for drugs used to treat wet age-related macular degeneration. (Washington) (DC): Dept of Health & Human Services; 2012. Publication OEI-03-10-00360.
   Google Scholar
• cited 2023 Jul 18. https://www.aao.org/eyenet/article/expensive-drugs
   Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion. The SCORE2 randomized clinical trial. JAMA. 2017;317(20):2072–2087. doi: 10.1001/jama.2017.4568
   PubMed Web of Science ®Google Scholar
• Scott IU, VanVeldhuisen PC, Ip MS, et al. Comparison of monthly vs treat-and-extend regimens for individuals with macular edema who Respond well to anti–vascular endothelial growth factor medications. Secondary outcomes from the SCORE2 randomized clinical trial. JAMA Ophthalmol. 2018;136(4):337–345. doi: 10.1001/jamaophthalmol.2017.6843
   PubMed Web of Science ®Google Scholar
• Khurana RN, Oden NL, VanVeldhuisen PC, et al. Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents: SCORE2 report 14: secondary analysis of the SCORE2 clinical trial. Graefes Arch Clin Exp Ophthalmol. 2021;259(7):1839–1851. doi: 10.1007/s00417-020-05018-7
   PubMed Web of Science ®Google Scholar
• Eadie JA, Ip MS, Kulkarni AD. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina. 2014;34(12):2439–2443. doi: 10.1097/IAE.0000000000000238
   PubMed Web of Science ®Google Scholar
• Lehmann‑Clarke L, Dirani A, Mantel I, et al. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion. Klin Monbl Augenheilkd. 2015;232(4):552–555. doi: 10.1055/s-0035-1545783
   PubMed Web of Science ®Google Scholar
• Pfau M, Fassnacht‑Riederle H, Becker MD, et al. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res. 2015;54(3):150–156. doi: 10.1159/000439223
   PubMed Web of Science ®Google Scholar
• Papakostas TD, Lim L, van Zyl T, et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond). 2016;30(1):79–84. doi: 10.1038/eye.2015.175
   PubMed Web of Science ®Google Scholar
• for the SCORE2 Investigator Group, Ip MS, Oden NL, et al. Month 12 outcomes after treatment change at month 6 among poor responders to aflibercept or bevacizumab in eyes with macular edema secondary to central or hemiretinal vein occlusion. A secondary analysis of the SCORE2 study. JAMA Ophthalmol. 2019;137(3):281–287.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmol. 2020;127(1):72–84. doi: 10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022;238:157–172. doi: 10.1016/j.ajo.2022.01.004
   PubMed Web of Science ®Google Scholar
• Assessing the efficacy and safety of brolucizumab versus aflibercept in patients with visual impairment due to macular edema secondary to central retinal vein occlusion (RAVEN). cited 2023 Jul 23. https://classic.clinicaltrials.gov/ct2/show/NCT03810313
   Google Scholar
• Khanani AM, Brown DM, Jaffe GJ, et al. On behalf of the MERLIN investigators. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmol. 2022;129(9):974–985. doi: 10.1016/j.ophtha.2022.04.028
   PubMed Web of Science ®Google Scholar
• Novartis halts three Beovu studies, cites patient safety. cited 2023 Jul 23. https://www.healio.com/news/ophthalmology/20210529/novartis-halts-three-beovu-studies-cites-patient-safety
   Google Scholar
• Sharma A, Hafeez Faridi M, Kumar N, et al. Immunogenicity and efficacy after switching from original ranibizumab to a ranibizumab biosimilar: real-world data. Eye. 2020;34(6):1008–1009. doi: 10.1038/s41433-019-0745-z
   PubMed Web of Science ®Google Scholar
• Sharma A, Kumar N, Kuppermann BD, et al. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019;33(9):1359–1361. doi: 10.1038/s41433-019-0434-y
   PubMed Web of Science ®Google Scholar
• Heier JS, Khanani AM, Ruiz CQ, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi: 10.1016/S0140-6736(22)00010-1
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–755. doi: 10.1016/S0140-6736(22)00018-6
   PubMed Web of Science ®Google Scholar
• New phase III data show Genentech’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO). cited Jul 30, 2023. https://www.gene.com/media/press-releases/14983/2023-02-09/new-phase-iii-data-show-genentechs-vabys
   Google Scholar
• High-dose aflibercept in wet AMD and DME provides therapeutic benefits, no New safety signals. cited 2023 Jul 30. https://www.ajmc.com/view/high-dose-aflibercept-in-wet-amd-and-dme-provide-therapeutic-benefits-no-new-safety-signals
   Google Scholar
• cited Jul 30. 2023. https://www.bayer.com/media/en-us/bayer-initiates-phase-iii-study-to-investigate-aflibercept-8-mg-in-retinal-vein-occlusion/
   Google Scholar
• cited 2023 Jul 30. https://www.hcplive.com/view/fda-issues-complete-response-letter-aflibercept-8-mg-amd-dme
   Google Scholar
• Kapur M, Nirula S, Naik MP. Future of anti‑VEGF: biosimilars and biobetters. Int J Retin Vitr. 2022;8(1):1–8. doi: 10.1186/s40942-021-00343-3
   PubMedGoogle Scholar
• Outlook Therapeutics Inc. Outlook therapeutics announces FDA acceptance of IND for ONS-5010. Press Release. 2019 Apr 1. cited Jul 30, 2023.
   Google Scholar
• Holekamp NM, Campochiaro PA, Chang MA. On behalf of archway investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmol. 2022;129(3):295–307. doi: 10.1016/j.ophtha.2021.09.016
   PubMed Web of Science ®Google Scholar
• cited 2023 Jul 30. https://www.gene.com/download/pdf/Susvimo_DHCP_Important_Prescribing_Information_2022-10-18.pdf
   Google Scholar
• cited 2023 Jul 31. https://www.aao.org/eyenet/article/gene-therapy-for-amd.
   Google Scholar
• FDA. Hospital and health system compounding under the federal food, drug, and cosmetic act: guidance for industry. 2016 Apr. at cited 2023 Jul 31. https://www.fda.gov/media/97353/download
   Google Scholar